Loading clinical trials...
Loading clinical trials...
A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP)
Conditions
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM
Standard Therapy plus continuous glucose monitoring (CGM)
Locations
21
United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Emory University School of Medicine
Atlanta, Georgia, United States
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States
Northwestern University
Chicago, Illinois, United States
Baltimore VA Medical Center
Baltimore, Maryland, United States
Boston Medical Center Corporation
Boston, Massachusetts, United States
Start Date
June 1, 2023
Primary Completion Date
September 24, 2024
Completion Date
September 24, 2024
Last Updated
February 19, 2026
NCT06579404
NCT06311019
NCT06268808
NCT05893797
NCT04585191
NCT05111301
Lead Sponsor
Tandem Diabetes Care, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions